Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018)

Neogenomics (NEO) posted Non-Current Deffered Revenue of $1.2 million for Q3 2018, up 85.03% quarter-over-quarter from $648000.0 in Q2 2018.

Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends

Neogenomics (NEO) has reported Non-Current Deffered Revenue for 2 consecutive years, with $1.2 million the latest figure, recorded in Q3 2018.

Non-Current Deffered Revenue for Q3 2018 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2018 was $1.2 million (changed N/A YoY), and the FY2017 annual result was $283000.0, changed N/A from the prior year.
Non-Current Deffered Revenue was $1.2 million for Q3 2018 at Neogenomics, up from $648000.0 in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $1.2 million in Q3 2018 and troughed at $283000.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn	-
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn	-
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn	-
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn	32.31 Mn
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn	17.00 Mn
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn	-
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn	-
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn	-
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn	-
10	Neogenomics	1.93 Bn	1.79 Bn	80.86 Mn	-

Download Data